

23.02.2023

08:25 - 08:29	Type: Welcome and closure Title: Welcome	Auditorium 113
08:30 - 09:50	Type: Educational session Title: Treatment of ovarian cancer in 2023 Moderation: Isabelle Ray-Coquard, France; Susana Banerjee, United Kingdom	Auditorium 113
08:30 - 08:35	Introduction <u>S. Banerjee</u> , The Royal Marsden Hospital - Chelsea, London, United Kingdom	
08:35 - 08:50	Do we still need radical surgery in the PARP inhibitor era? <u>G. Scambia</u> , Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy	
08:50 - 09:05	How to select the best first line maintenance treatment? Is molecular profiling the only criteria to choose? <u>I. Ray-Coquard</u> , Centre Léon Bérard, Lyon, France	
09:05 - 09:20	New treatment in the current ovarian cancer beyond ADCs <u>N. Colombo</u> , IEO - Istituto Europeo di Oncologia, Milan, Italy	
09:20 - 09:35	PARP inhibitors: Mechanism of resistance and how to overcome <u>I. Mcneish</u> , Imperial College London - Hammersmith Hospital, London, United Kingdom	
09:35 - 09:50	Q&A	
09:50 - 10:15	Type: Coffee break Title: Coffee break	Exhibition and Poster area

10:15 - 11:35	Type: Special Symposium Title: How to interpret overall survival data with PARP inhibitors Moderation: Robert Coleman, United States of America; Susana Banerjee, United Kingdom	Auditorium 113
10:15 - 10:30	Why are we having this Symposium? Recent regulatory actions by FDA/EMA regarding late-stage approval for PARPi in recurrent ovarian cancer <u>R. Coleman</u> , US Oncology Research, The Woodlands, United States of America	
10:30 - 10:45	Is there clinical evidence to support the link between PARPi use and a negative impact on OS? <u>J. Ledermann</u> , UCL Cancer Institute - UCL - London's Global University, London, United Kingdom	
10:45 - 11:00	Is there a biological rationale to support decremental impact on overall survival? <u>A.J. Gonzalez Martin</u> , Clinica Universidad de Navarra, Madrid, Spain	
11:00 - 11:15	What is the impact of overall survival results of PARP inhibitor trials? <u>S. Banerjee</u> , The Royal Marsden Hospital - Chelsea, London, United Kingdom	
11:15 - 11:35	Q&A	

11:45 - 12:45	Type: Proffered Paper session Title: Proffered Paper session Moderation: Bradley Monk, United States of America; Domenica Lorusso, Italy	Auditorium 113
11:45 - 11:53	320 - 5-year (y) overall survival (OS) with maintenance olaparib (ola) plus bevacizumab (bev) by clinical risk in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) in the Phase III PAOLA-1/ENGOT-ov25 trial <u>D. Lorusso</u> , Istituto Tumori Milano + Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Catholic University of Sacred Heart, and MITO, Rome, Italy	
11:53 - 12:01	330 - PRIMA/ENGOT-OV26/GOG-3012 study: long-term conditional PFS <u>A.J. Gonzalez Martin</u> , Clínica Universidad de Navarra, Madrid, Program in Solid Tumours, CIMA, Pamplona, and Grupo Español de Investigación en Cáncer de Ovario (GEICO), Madrid, Spain	
12:01 - 12:11	Invited Discussant of abstracts 320 and 330 <u>K. Moore</u> , Stephenson Cancer Center/University of Oklahoma, Oklahoma City, United States of America	
12:11 - 12:19	340 - ATR inhibitor alone (ceralasertib) or in combination with olaparib in gynaecological cancers with ARID1A loss or no loss - results from the ENGOT/GYN1/NCRI ATARI trial <u>S. Banerjee</u> , The Royal Marsden Hospital & The Institute of Cancer Research, London, United Kingdom	
12:19 - 12:24	Invited Discussant of abstract 340	
12:24 - 12:32	350 - Overall Survival of Niraparib with Individualized Starting Dose as Maintenance Therapy in Patients with Platinum-Sensitive Recurrent Ovarian Cancer Adjusted for Subsequent PARPi Use in Placebo Group: Results from an Ad Hoc Interim Analysis for the Phase 3 NORA Study <u>X. Wu</u> , Fudan University Shanghai Cancer Center, Shanghai, China	
12:32 - 12:37	Invited Discussant of abstract 350 <u>J. Ledermann</u> , UCL Cancer Institute - UCL - London's Global University, London, United Kingdom	
12:37 - 12:45	Q&A and discussion	
13:45 - 14:45	Type: Industry satellite symposium Title: GSK- Industry satellite symposium 1	Auditorium 113

15:00 - 16:00	Type: Controversy session Title: How hot is HIPEC treatment in ovarian cancer? Moderation: Robert Coleman, United States of America	Auditorium 113
15:00 - 15:10	Introduction and first vote <u>R. Coleman</u> , US Oncology Research, The Woodlands, United States of America	
15:10 - 15:30	The data absolutely support integration of HIPEC into primary ovarian cancer management (PRO) <u>W. Van Driel</u> , NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands	
15:30 - 15:50	HIPEC is not "IT" (CON) <u>L. Randall</u> , Virginia Commonwealth University Medical College of Virginia Campus, Richmond, United States of America	
15:50 - 16:00	Second vote and conclusions <u>R. Coleman</u> , US Oncology Research, The Woodlands, United States of America	
16:00 - 16:30	Type: Coffee break Title: Coffee break	Exhibition and Poster area

16:30 - 17:50	Type: Educational session Title: ADCs in gynaecological cancers Moderation: Bradley Monk, United States of America; Nicole Concin, Austria	Auditorium 113
16:30 - 16:35	Introduction <u>B. Monk</u> , The GOG Foundation, Inc., Edgewater, United States of America	
16:35 - 16:50	Understanding the basics: Structure, key properties, mechanism of action, optimal diagnostic test to determine the target <u>K. Moore</u> , Stephenson Cancer Center/University of Oklahoma, Oklahoma City, United States of America	
16:50 - 17:05	The evolving ADC treatment landscape in ovarian cancer <u>N. Concin</u> , Landeskrankenhaus - Universitaetskliniken Innsbruck, Innsbruck, Austria	
17:05 - 17:20	Role of ADCs in cervical cancer treatment in the era of immunotherapy <u>B. Monk</u> , The GOG Foundation, Inc., Edgewater, United States of America	
17:20 - 17:35	The new challenge: ADC class effects, on/off-target adverse reactions and their interdisciplinary management <u>T. Van Gorp</u> , University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium	
17:35 - 17:50	Q&A	

18:00 - 19:00	Type: ESMO Colloquium Title: ESMO Colloquium supported by Eisai Europe Ltd. - Management of patients with advanced endometrial cancer in the era of molecular oncology and immunotherapy Moderation: Vicky Makker, United States of America; Alexandra Leary, France	Auditorium 113
18:00 - 18:05	Introduction <u>V. Makker</u> , Memorial Sloan-Kettering Cancer Center, New York City, United States of America	
18:05 - 18:20	Emerging molecular profiling models for advanced endometrial cancer: Prognosticators and predictors of benefit from IO and targeted therapeutics <u>T. Bosse</u> , Leiden University Medical Center, Leiden, Netherlands	
18:20 - 18:35	The landscape of approved immune checkpoint inhibitors and TKI combinations in advanced endometrial cancer <u>V. Makker</u> , Memorial Sloan-Kettering Cancer Center, New York City, United States of America	
18:35 - 18:50	Research insights: New immunotherapy combinations in clinical development for gynecological malignancies <u>A. Leary</u> , Institut Gustave Roussy, Villejuif, France	
18:50 - 18:55	Q&A	
18:55 - 19:00	Conclusions and wrap-up <u>A. Leary</u> , Institut Gustave Roussy, Villejuif, France	
19:15 - 20:15	Type: Industry satellite symposium Title: (VIRTUAL ONLY) AstraZeneca- Industry satellite symposium	Auditorium 113

24.02.2023

08:30 - 09:50 **Type: Educational session** **Auditorium 113**
Title: Is cervical cancer still an orphan disease?
Moderation: Kosei Hasegawa, Japan; Bradley Monk, United States of America

08:30 - 08:35 **Introduction**
K. Hasegawa, Saitama Medical University International Medical Center, Saitama, Japan

08:35 - 08:50 **Molecular profiling and pathology of cervical cancer patients: Are HPV negative tumors a different entity?**
C. Krakstad, Haukeland University Hospital, Bergen, Norway

08:50 - 09:05 **Can we improve the prognosis of locally advanced cervical cancer?**
K. Hasegawa, Saitama Medical University International Medical Center, Saitama, Japan

09:05 - 09:20 **Immunotherapy in cervical cancer: A paradigm shift**
D. Lorusso, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, Italy

09:20 - 09:35 **Innovative techniques in radiation oncology to increase cure and reduce toxicity**
D. Najjari Jamal, Catalan Institute of Oncology (ICO), IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain

09:35 - 09:50 **Q&A**

09:50 - 10:15 **Type: Coffee break** **Exhibition and Poster area**
Title: Coffee break

10:15 - 11:35	Type: Educational session Title: Endometrial cancer Moderation: Ana Oaknin, Spain; Domenica Lorusso, Italy	Auditorium 113
10:15 - 10:20	Introduction <u>D. Lorusso</u> , Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, Italy	
10:20 - 10:35	Revisiting the adjuvant therapy in endometrial cancer: ESMO Guidelines <u>C. Creutzberg</u> , LUMC - Universitair Medisch Centrum, Leiden, Netherlands	
10:35 - 10:50	Is immunotherapy changing the face of recurrent/metastatic endometrial cancer? <u>A. Oaknin</u> , Vall d'Hebron University Hospital, Barcelona, Spain	
10:50 - 11:05	Are all dMMR/MSI-H endometrial cancer the same disease? <u>X. Matias-Guiu</u> , IDIBELL - Bellvitge Biomedical Research Institute, Hospitalet de Llobregat, Spain	
11:05 - 11:20	Beyond immunotherapy: What is the role of HER2, p53 and other molecular targets in the recurrent/metastatic endometrial cancer treatment landscape? <u>M.R. Mirza</u> , Rigshospitalet, Copenhagen, Denmark	
11:20 - 11:35	Q&A	
11:45 - 12:15	Type: Keynote lecture Title: Keynote address Moderation: Domenica Lorusso, Italy; Susana Banerjee, United Kingdom	Auditorium 113
11:45 - 11:50	Introduction to the Keynote lecture <u>D. Lorusso</u> ¹ , <u>S. Banerjee</u> ² , ¹ Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, Italy, ² The Royal Marsden Hospital - Chelsea, London, United Kingdom	
11:50 - 12:15	Pandemomics: Challenging assumptions in gynecologic oncology <u>M. Bookman</u> , Kaiser Permanente Medical Center, San Francisco, United States of America	
12:15 - 13:00	Type: Industry satellite symposium Title: (ON-SITE ONLY) Regeneron- Meet the expert	Room 122
13:15 - 14:15	Type: Industry satellite symposium Title: Seagen - Industry satellite symposium 3	Auditorium 113

14:30 - 15:50	Type: Multidisciplinary Tumour Board Title: Rare cancers Moderation: Domenica Lorusso, Italy; Isabelle Ray-Coquard, France	Auditorium 113
14:30 - 14:35	Introduction <u>I. Ray-Coquard</u> , Centre Léon Bérard, Lyon, France	
14:35 - 14:55	State-of-the-art management in carcinosarcoma: From the biology to treatment <u>I. Romero</u> , IVO - Fundación Instituto Valenciano de Oncología, Valencia, Spain	
14:55 - 15:15	Is immune therapy definitely required for all clear cell carcinoma? <u>A. Leary</u> , Institut Gustave Roussy, Villejuif, France	
15:15 - 15:35	Which drugs could be relevant for LGSC: The present and future <u>C. Gourley</u> , Cancer Research UK Edinburgh Centre, Edinburgh, United Kingdom	
15:35 - 15:50	Q&A	
15:50 - 16:15	Type: Coffee break Title: Coffee break	Exhibition and Poster area
16:15 - 17:30	Type: Mini Oral session Title: Mini Oral session Moderation: Susana Banerjee, United Kingdom; Kosei Hasegawa, Japan	Auditorium 113
16:15 - 16:20	36MO - Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (OC): 5-year (y) progression-free survival (PFS) by molecular subgroup in the PAOLA-1/ENGOT-ov25 trial <u>A.J. Gonzalez Martin</u> , Clinica Universidad de Navarra, and GEICO, Madrid, Spain	
16:20 - 16:25	37MO - Niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: a post hoc analysis on efficacy by surgical timing and residual disease status in the phase III PRIME trial <u>L. Pan</u> , Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China	
16:25 - 16:35	Invited Discussant of abstracts 36MO and 37MO <u>R. Kristeleit</u> , Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom	
16:35 - 16:40	22MO - Homologous Recombination Gene Mutations in Uterine Serous Cancer: A Phenotype of the Hereditary Breast and Ovarian Cancer Syndrome? <u>M.D. Ahsan</u> , Weill Cornell Medicine, New York, United States of America	
16:40 - 16:45	38MO - Validation study of the shallowHRDv2 assay for Homologous Recombination Deficiency (HRD) detection in high-grade ovarian carcinomas (HGOC) in the first-line setting, from the phase III PAOLA-1/ENGOT-ov25 trial	

C. Callens, Institut Curie, Paris, France

16:45 - 16:50	39MO - Clinical evaluation of a low-coverage whole-genome test for homologous recombination deficiency detection in ovarian cancer <u>R. Boidot</u> , Centre Georges-François Leclerc (Dijon), Dijon, France	
16:50 - 16:55	1MO - Identification of RAD51 foci in cancer-associated circulating cells and their association with treatment outcomes, in patients with high-grade serous ovarian cancer (HGSOC) <u>M. Hall</u> , Mount Vernon Cancer Centre, Beaconsfield, United Kingdom	
16:55 - 17:10	Invited Discussant of abstracts 22MO, 38MO, 39MO and 1MO <u>I. Mcneish</u> , Imperial College London - Hammersmith Hospital, London, United Kingdom	
17:10 - 17:15	40MO - Targetable Gene Mutations in Mucinous Ovarian Cancer <u>S. Levi</u> , Weill Cornell Medicine, New York, United States of America	
17:15 - 17:20	74MO - Clinical outcomes for pelvic node-positive vulvar carcinoma in the PET and IMRT era: reassessing the Stage IVb designation <u>S. Koerner</u> , UPMC Hillman Cancer Center, Pittsburgh, United States of America	
17:20 - 17:30	Invited Discussant of abstracts 40MO and 74MO <u>R. Coleman</u> , US Oncology Research, The Woodlands, United States of America	
17:35 - 17:40	Type: Welcome and closure Title: Closing	Auditorium 113
23:00 - 23:59	Type: Keynote lecture Title: SESSION TEST - ITDS Moderation: Simona Tettamanti, Switzerland	Auditorium 113